H5 Vaccine Alone or With Aluminum Hydroxide in Elderly Adults

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

March 31, 2007

Study Completion Date

March 31, 2007

Conditions
Influenza
Interventions
BIOLOGICAL

Aluminum hydroxide

Aluminum hydroxide adjuvant.

BIOLOGICAL

Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)

Inactivated monovalent subvirion influenza H5N1 vaccine. Supplied in 0.5 mL unit dose vials as a sterile solution for IM injection. Dosages: 45 mcg, 15 mcg, 7.5, mcg, or 3.75 mcg administered with or without aluminum hydroxide adjuvant on Days 0 and 28.

Trial Locations (7)

14642

University of Rochester, Rochester

21201

University of Maryland Baltimore, Baltimore

52242

University of Iowa, Iowa City

63104

Saint Louis University, St Louis

77030

Baylor College of Medicine, Houston

45229-3039

Cincinnati Children's Hospital Medical Center, Cincinnati

37232-2573

Vanderbilt University - Pediatric - Vanderbilt Vaccine Research Center, Nashville

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00294099 - H5 Vaccine Alone or With Aluminum Hydroxide in Elderly Adults | Biotech Hunter | Biotech Hunter